Valentas and Arnipin tablets are available in 200 mg, 100 mg, and 50 mg
Lupin has launched combination drug Sacubitril and Valsartan under two brand names, Valentas and Arnipin, in India.
This drug combination is indicated for patients with Heart Failure (HF) conditions. Valentas and Arnipin tablets are available in 200 mg, 100 mg, and 50 mg.
Valentas and Arnipin are indicated to reduce repeated hospitalization and the risk of cardiovascular death among adult patients with chronic mild to moderate heart failure.
Rajeev Sibal, President – India Region Formulations, Lupin said, “As a leader in the cardiac therapy area, Lupin is committed to offering patients with treatment options that limit the need for hospitalization and reduce the risk of death. The launch of Valentas and Arnipin aligns with this commitment and offers patients an important treatment option and fulfils an unmet need while reducing the cost of therapy.”
